Elucidating the role of the Fes tyrosine kinase in breast cancer

Fes was first discovered as a protein-tyrosine kinase-encoded by the v-fes retroviral oncogene. Retrovirally encoded Fes oncoproteins induced tumors in chickens and cats and cause tumors in transgenic mice; however, a role for Fes in human cancer has not been established. This thesis identifies tumo...

Full description

Bibliographic Details
Main Author: Zhang, Connie
Other Authors: Queen's University (Kingston, Ont.). Theses (Queen's University (Kingston, Ont.))
Language:en
en
Published: 2013
Subjects:
Online Access:http://hdl.handle.net/1974/8527
id ndltd-LACETR-oai-collectionscanada.gc.ca-OKQ.1974-8527
record_format oai_dc
spelling ndltd-LACETR-oai-collectionscanada.gc.ca-OKQ.1974-85272013-12-20T03:41:07ZElucidating the role of the Fes tyrosine kinase in breast cancerZhang, ConniePathologyBreast cancer researchFes was first discovered as a protein-tyrosine kinase-encoded by the v-fes retroviral oncogene. Retrovirally encoded Fes oncoproteins induced tumors in chickens and cats and cause tumors in transgenic mice; however, a role for Fes in human cancer has not been established. This thesis identifies tumor promoting roles of Fes through effects on stromal cells using genetic mouse models. First, in an orthotopic mouse mammary gland engraftment model, I found that loss of Fes in the host correlated with reductions in engrafted tumor growth rates, metastasis and circulating tumor cells, which may be partly due to reduced vascularity and fewer tumor-associated macrophages. We also showed Fes-deficient macrophages were less capable of promoting tumor cell invasion in co-culture experiments. Next, I observed delayed tumor onset in the absence of Fes in a transgenic mouse model of breast cancer driven by an activated HER2/Neu allele. This longer tumor latency correlated with hyperinflammatory status of Fes-deficient normal mammary glands. Taken together, these observations argue that Fes inhibition might provide therapeutic benefits in breast cancer, by attenuating tumor-associated angiogenesis and the metastasis-promoting functions of tumor-associated macrophages, or by delaying breast tumor onset in women with HER2 overexpression. Finally, we showed that mice engrafted with IL-4 producing tumor cells developed tumors with significantly reduced growth rates and a complete attenuation of lung metastasis, which correlated with increased numbers of macrophages and enhanced phagocytic capability of macrophages in the tumor microenvironment. These observations suggest that IL-4 could be a good candidate for immunotherapy.Thesis (Ph.D, Pathology & Molecular Medicine) -- Queen's University, 2013-12-18 11:44:40.294Queen's University (Kingston, Ont.). Theses (Queen's University (Kingston, Ont.))2013-12-18 11:44:40.2942013-12-18T16:56:30Z2013-12-18Thesishttp://hdl.handle.net/1974/8527enenCanadian thesesThis publication is made available by the authority of the copyright owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted by the copyright laws without written authority from the copyright owner.
collection NDLTD
language en
en
sources NDLTD
topic Pathology
Breast cancer research
spellingShingle Pathology
Breast cancer research
Zhang, Connie
Elucidating the role of the Fes tyrosine kinase in breast cancer
description Fes was first discovered as a protein-tyrosine kinase-encoded by the v-fes retroviral oncogene. Retrovirally encoded Fes oncoproteins induced tumors in chickens and cats and cause tumors in transgenic mice; however, a role for Fes in human cancer has not been established. This thesis identifies tumor promoting roles of Fes through effects on stromal cells using genetic mouse models. First, in an orthotopic mouse mammary gland engraftment model, I found that loss of Fes in the host correlated with reductions in engrafted tumor growth rates, metastasis and circulating tumor cells, which may be partly due to reduced vascularity and fewer tumor-associated macrophages. We also showed Fes-deficient macrophages were less capable of promoting tumor cell invasion in co-culture experiments. Next, I observed delayed tumor onset in the absence of Fes in a transgenic mouse model of breast cancer driven by an activated HER2/Neu allele. This longer tumor latency correlated with hyperinflammatory status of Fes-deficient normal mammary glands. Taken together, these observations argue that Fes inhibition might provide therapeutic benefits in breast cancer, by attenuating tumor-associated angiogenesis and the metastasis-promoting functions of tumor-associated macrophages, or by delaying breast tumor onset in women with HER2 overexpression. Finally, we showed that mice engrafted with IL-4 producing tumor cells developed tumors with significantly reduced growth rates and a complete attenuation of lung metastasis, which correlated with increased numbers of macrophages and enhanced phagocytic capability of macrophages in the tumor microenvironment. These observations suggest that IL-4 could be a good candidate for immunotherapy. === Thesis (Ph.D, Pathology & Molecular Medicine) -- Queen's University, 2013-12-18 11:44:40.294
author2 Queen's University (Kingston, Ont.). Theses (Queen's University (Kingston, Ont.))
author_facet Queen's University (Kingston, Ont.). Theses (Queen's University (Kingston, Ont.))
Zhang, Connie
author Zhang, Connie
author_sort Zhang, Connie
title Elucidating the role of the Fes tyrosine kinase in breast cancer
title_short Elucidating the role of the Fes tyrosine kinase in breast cancer
title_full Elucidating the role of the Fes tyrosine kinase in breast cancer
title_fullStr Elucidating the role of the Fes tyrosine kinase in breast cancer
title_full_unstemmed Elucidating the role of the Fes tyrosine kinase in breast cancer
title_sort elucidating the role of the fes tyrosine kinase in breast cancer
publishDate 2013
url http://hdl.handle.net/1974/8527
work_keys_str_mv AT zhangconnie elucidatingtheroleofthefestyrosinekinaseinbreastcancer
_version_ 1716621781979103232